dc.contributor.author |
Wihastuti, Titin Andri |
|
dc.contributor.author |
Lestari, Rosaria Dian |
|
dc.contributor.author |
Heriansyah, Teuku |
|
dc.date.accessioned |
2021-10-14T01:50:45Z |
|
dc.date.available |
2021-10-14T01:50:45Z |
|
dc.date.issued |
2018-04-29 |
|
dc.identifier.issn |
2231-3354 |
|
dc.identifier.uri |
https://www.japsonline.com/admin/php/uploads/2601_pdf.pdf |
|
dc.identifier.uri |
http://repository.unisma.ac.id/handle/123456789/2036 |
|
dc.description |
[ARCHIVES] Copyright Article from: Journal of Applied Pharmaceutical Science |
en_US |
dc.description.abstract |
Atherosclerosis is the main cause of mortality and morbidity globally. Lipoprotein-associated phospholipase A2
(LpPLA2
) activity is suspected to have a significant role in atherosclerosis. 50 Sprague-Dawley Rats were divided into
five groups: normal, dyslipidemia, Type 2 diabetes mellitus (T2DM), dyslipidemia with darapladib administration
and T2DM with darapladib administration. These groups were divided into two serial times: 8 and 16 weeks.
mRNA Lp-PLA2
was measured from blood and aortic tissue extraction. Aortic tissue Lp-PLA2
was measured by
immunofluorescence. Lp-PLA2
expression in aortic tissue was consistently increased in dyslipidemia and T2DM.
The expression of Lp-PLA2
enzymatic was significantly suppressed (p < 0.05) with the administration of darapladib
especially in 8 weeks groups in both dyslipidemia and T2DM. The administration of darapladib in dyslipidemia
and T2DM didn’t significantly suppress the expression of mRNA Lp-PLA2
in blood and aortic tissue. The failure
of genetic expression suppression of Lp-PLA2
was found in both 8 weeks and 16 weeks groups. The expression of
Lp-PLA2
protein also showed an inclined difference between dyslipidemia and T2DM. These results showed that
administration of darapladib significantly decreased Lp-PLA2
protein but prone to increase the expression of mRNA
Lp-PLA2 in blood and aortic tissue in dyslipidemia and T2DM model |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Journal of Applied Pharmaceutical Science |
en_US |
dc.relation.ispartofseries |
Journal of Applied Pharmaceutical Science;Vol.8, Issue 4, Page 64-70 |
|
dc.subject |
Darapladib |
en_US |
dc.subject |
Dyslipidemia |
en_US |
dc.subject |
Atherosclerosis |
en_US |
dc.subject |
T2DM |
en_US |
dc.subject |
Lp-PLA2 |
en_US |
dc.title |
The Effect of Darapladib Therapy for the Expression of Lp-PLA2 in Dyslipidemia and Type 2 Diabetes Mellitus Atherosclerosis Model |
en_US |
dc.type |
Article |
en_US |